It’s common for patients to want to know more about what’s causing them to be ill and their DMD diagnosis and it’s the same for their families – however long that road may be.
Summit Therapeutics has axed development of its Duchenne muscular dystrophy drug ezutromid after a spectacular failure in phase 2, causing the UK biotech's shares to plunge.
Everyone wants to find a cure for a debilitating long-term condition, but what can often be overlooked is the value in being able to first make life more manageable, comfortable or enjoyabl
US biotech Sarepta's shares jumped by as much as 60% after a gene therapy produced dramatic results in three boys with the muscle wasting disease Duchenne muscular dystrophy (DMD).
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
